Xencor Inc XNCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
-
Xencor Announces Proposed Public Offering of Common Stock
-
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
-
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
-
Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends
-
Xencor Reports Second Quarter 2024 Financial Results
-
Xencor: J&J's Janssen Termintates Rights to Plamotamab
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 280
- Website
- https://www.xencor.com
Comparables
Valuation
|
Metric
|
XNCR
|
ARVN
|
SWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.22 | 2.83 | 4.31 |
Price/Sales | 9.28 | 11.73 | 25.81 |
Price/Cash Flow | — | — | — |
Price/Earnings
XNCR
ARVN
SWTX
Financial Strength
|
Metric
|
XNCR
|
ARVN
|
SWTX
|
|---|---|---|---|
Quick Ratio | 6.62 | 3.57 | 7.49 |
Current Ratio | 6.92 | 3.62 | 7.91 |
Interest Coverage | — | — | — |
Quick Ratio
XNCR
ARVN
SWTX
Profitability
|
Metric
|
XNCR
|
ARVN
|
SWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −12.57% | −22.33% | −32.86% |
Return on Equity (Normalized) | −16.62% | −47.53% | −37.78% |
Return on Invested Capital (Normalized) | −17.76% | −54.26% | −42.13% |
Return on Assets
XNCR
ARVN
SWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pdkvfxjbj | Bft | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mzsblbj | Bsnjdm | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ngsbrhl | Rvqcyg | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yqkxqhyr | Pgcffz | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Fnybkyg | Vvkk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fdbxvznq | Smym | $28.1 Bil | |||
| Moderna Inc
MRNA
| Dxfvbzf | Mbmgz | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Lyddqcgx | Fbxz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ndjfkqctd | Yxklvkq | $13.4 Bil | |||
| Incyte Corp
INCY
| Xhxtqqd | Sfdbvf | $12.7 Bil |
United States